SGLT-2 Therapy Center

The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …

Glutamine is the most abundant amino acid in the human body and is involved in more metabolic processes than any other amino acid. Recent studies using isotopic and balance techniques have greatly advanced the understanding of glutamine metabolism in humans and its role in glucose metabolism in the kidney and other …

  SGLT-2 inhibitor use in the management of glucose in type 2 diabetes could reduce blood pressure in patients with hypertension…. In a new study, researchers found that empagliflozin lowered blood pressure in patients with type 2 diabetes and hypertension. Hypertension affects about two-thirds of patients with diabetes. See more …

Pilot study shows that an SGLT-2 inhibitor doses of 5-mg and 10-mg were associated with significant reductions in blood glucose and total daily insulin dose…. Dapagliflozin is a member of the SGLT2 inhibitor class of diabetic medications indicated only for treatment of type 2 diabetes. Dapagliflozin helps reduce blood glucose …

Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, …

This week, we are taking a break from our Clinical Text presentations, to bring you this exclusive interview with Al Mann, the legendary founder of Mannkind Corp, and the person primarily responsible for backing the development of the inhaled insulin product, Afrezza, soon to be on the market. Steve Freed: …

As the diabetes epidemic continues to grow, practitioners are increasingly searching for medication solutions that can help patients to better manage their diabetes. This month, we have a recent slides series from the ADA showing the positive effects of adding-on SGLT-2 inhibitors to the medication regimen of patients on DPP-4’s …

The glucose-reducing drug empagliflozin (Jardiance) now has approval from the FDA after the drug maker corrected manufacturing problems that caused the agency to say “no” in March…. The sodium glucose cotransporter 2 (SGLT2) is indicated for improving glycemic control in adults with type 2 diabetes in conjunction with diet and …

In this last of a comprehensive series of four Homerun Slides sets on SGLT-2 inhibitors, we delve deeper into how this drug class can work in challenging patient populations, incuding older and renally-impaired patients. In addition, the beneficial effects on weight and blood pressure are discussed…. To download the complete …

In this third set of a series of four Homerun Slides on SGLT-2 inhibitor medications, we cover LX4211, an SGLT-1 and SGLT-2 dual inhibitor, and then explore some of the safety concerns around SGLT-2 inhibitors including the safety of this drug class for older patients. We also review some of …